Page last updated: 2024-11-11

br-x 537a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bromolasalocid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5484221
CHEMBL ID356117
MeSH IDM0093023

Synonyms (18)

Synonym
bromolasalocid
CHEMBL356117
3-bromo-2-[(3r,4s,5s,7r)-7-[(2s,3s,5s)-5-ethyl-5-[(2r,5r,6s)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-3-methyloxolan-2-yl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-6-hydroxy-5-methylbenzoic acid
unii-tm60rnt0ia
tm60rnt0ia ,
38784-08-6
brx 537a
br-x 537a
ro 20-0006
benzoic acid, 3-bromo-2-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-6-hydroxy-5-methyl-, (2r-(2alpha(2s*(3r*,4s*,5s*,7r*),3s*,5s*),5alpha,6beta))-
br-x-537a
antibiotic br-x 537a
5-bromolasalocid a
benzoic acid, 3-bromo-2-(7-(5-ethyl-5-(5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-6-hydroxy-5-methyl-, (2r-(2.alpha.(2s*(3r*,4s*,5s*,7r*),3s*,5s*),5.alpha.,6.beta.))-
benzoic acid, 3-bromo-2-((3r,4s,5s,7r)-7-((2s,3s,5s)-5-ethyl-5-((2r,5r,6s)-5-ethyltetrahydro-5-hydroxy-6-methyl-2h-pyran-2-yl)tetrahydro-3-methyl-2-furanyl)-4-hydroxy-3,5-dimethyl-6-oxononyl)-6-hydroxy-5-methyl-
Q27290018
1,4:5,9-dianhydro-1-[9-(6-bromo-2-carboxy-3-hydroxy-4-methylphenyl)-6-hydroxy-5,7-dimethyl-4-oxononan-3-yl]-2,3,6,7-tetradeoxy-4-ethyl-8-c-ethyl-2,9-dimethylnonitol
DTXSID50959594

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Bromolasalocid produces a relatively flat systolic blood pressure dose-response effect in the spontaneously hypertensive rat."( Bromolasalocid (Ro 20-0006) antihypertensive ionophore.
Cohen, MR; Kovzelove, F; Osborne, MW; Wenger, JJ, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID25581Dissociation constant was determined1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Cluster significance analysis contrasted with three other quantitative structure-activity relationship methods.
AID23451Partition coefficient (logP)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Cluster significance analysis contrasted with three other quantitative structure-activity relationship methods.
AID227520In vitro antibacterial activity was determined1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Cluster significance analysis contrasted with three other quantitative structure-activity relationship methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (52.63)18.7374
1990's6 (31.58)18.2507
2000's3 (15.79)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.14 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]